Gustavo Benfatti Olivato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gustavo Benfatti Olivato has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Mendes Awni Cidale
Department of Oncology, Hospital Sirio-Libanes, Sao Paulo, SP, Brazil
1 shared publication - Cassio Murilo Trovo Hidalgo Filho
Instituto do Câncer do Estado de São Paulo, University of São Paulo, São Paulo, Brazil
1 shared publication - Danillo Zeferino de Oliveira Souza
Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Sao Paulo, Brazil
1 shared publication - Felippe Lazar Neto
Department of Clinical Oncology Instituto do Câncer do Estado de São Paulo (ICESP) São Paulo Brazil
1 shared publication - Giulia Kodja Zanetta
Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil
1 shared publication - Heloisa Guedes Andrade
Instituto do Câncer do Estado de São Paulo, University of São Paulo, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 25 January 2026
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 22 (CP)
Tebentafusp in Metastatic Uveal Melanoma: A Case Series and Practical Guidance for Toxicity Management
Uveal melanoma (UM) is a rare malignancy with poor outcomes in the metastatic setting and limited benefit from conventional systemic therapies. Tebentafusp, a novel bispecific fusion protein targeting glycoprotein 100 (gp100) in human leukocyte antigen A (HLA-A)*02:01–positive patients, has recently demonstrated a survival advantage, being approved in Brazil in 2025. However, its distinct toxicity profile, particularly cytokine-release syndrome, rash, and liver enzyme elevations, remain unfamiliar to many clinicians. Reporting early real-world experiences can provide valuable practical guidance for managing these adverse events in routine practice. In this case series, we describe four adult HLA-A*02:01–positive patients with metastatic UM treated with tebentafusp at a single Brazilian center. All participants initiated therapy in an inpatient setting following standardized institutional routines designed for safe administration, including structured premedication, continuous monitoring, and predefined response algorithms for early infusion reactions. Across cases, predictable early reactions were successfully managed using protocol-based interventions—such as antihistamines, low-dose corticosteroids, intravenous fluids, and targeted supportive care—allowing uninterrupted dose escalation and subsequent transition to outpatient treatment. These cases illustrate the practical steps, decision pathways, and monitoring strategies that enable safe implementation of tebentafusp in real-world practice. This case series highlights the characteristic toxicities associated with tebentafusp and emphasizes the importance of early recognition and proactive management strategies to ensure treatment continuation. Our experience provides pragmatic insights that may support oncologists in Brazil as they begin to integrate tebentafusp into the care of patients with metastatic UM.
- 25 January 2026
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 22 (CP)
Open AccessTebentafusp in Metastatic Uveal Melanoma: A Case Series and Practical Guidance for Toxicity Management
Uveal melanoma (UM) is a rare malignancy with poor outcomes in the metastatic setting and limited benefit from conventional systemic therapies. Tebentafusp, a novel bispecific fusion protein targeting glycoprotein 100 (gp100) in human leukocyte antigen A (HLA-A)*02:01–positive patients, has recently demonstrated a survival advantage, being approved in Brazil in 2025. However, its distinct toxicity profile, particularly cytokine-release syndrome, rash, and liver enzyme elevations, remain unfamiliar to many clinicians. Reporting early real-world experiences can provide valuable practical guidance for managing these adverse events in routine practice. In this case series, we describe four adult HLA-A*02:01–positive patients with metastatic UM treated with tebentafusp at a single Brazilian center. All participants initiated therapy in an inpatient setting following standardized institutional routines designed for safe administration, including structured premedication, continuous monitoring, and predefined response algorithms for early infusion reactions. Across cases, predictable early reactions were successfully managed using protocol-based interventions—such as antihistamines, low-dose corticosteroids, intravenous fluids, and targeted supportive care—allowing uninterrupted dose escalation and subsequent transition to outpatient treatment. These cases illustrate the practical steps, decision pathways, and monitoring strategies that enable safe implementation of tebentafusp in real-world practice. This case series highlights the characteristic toxicities associated with tebentafusp and emphasizes the importance of early recognition and proactive management strategies to ensure treatment continuation. Our experience provides pragmatic insights that may support oncologists in Brazil as they begin to integrate tebentafusp into the care of patients with metastatic UM.
- 1 July 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2400063
Unplanned Hospital Admissions in Patients With Solid Tumors in Brazil: Causes and Progressive Disease's Impact on Outcomes
PURPOSE: Most patients with cancer will be hospitalized throughout the disease course. However, most evidence on the causes and outcomes of these hospitalizations comes from administrative data or small retrospective studies from high-income countries. METHODS: This study is a retrospective cohort of patients with solid tumors hospitalized from February 1, 2021, to December 31, 2021, in a tertiary cancer center in São Paulo, Brazil. We collected data on cancer diagnosis, symptoms at admission, hospitalization diagnosis, and survival clinical outcomes during in-hospital stay (in-hospital mortality) and after discharge (readmission rates and overall survival [OS]). Progressive disease (PD) diagnosis during admission was retrieved from manual chart review if explicitly stated by the attending physician. We modeled in-hospital mortality and postdischarge OS with logistic regression and Cox proportional hazards models, respectively. RESULTS: A total of 3,726 unique unplanned admissions were identified. The most common symptoms at admission were pain (40.6%), nausea (16.8%), and dyspnea (16.1%). PD (34.0%), infection (31.1%), and cancer pain (13.4%) were the most frequent reasons for admission. The in-hospital mortality rate was 18.9%. Patients with PD had a high in-hospital mortality rate across all tumor groups and higher odds of in-hospital death (odds ratio, 3.5 [95% CI, 3.0 to 4.2]). The 7-, 30-, and 90-day readmission rates were 11.9%, 33.5%, and 54%, respectively. The postdischarge median OS (mOS) was 12.6 months (95% CI, 11.6 to 13.7). Poorer postdischarge survival was observed among patients with PD (mOS, 5 months v 18 months; P < .001; hazard ratio, 2.4 [95% CI, 2.1 to 2.6]). CONCLUSION: PD is a common diagnosis during unplanned hospitalizations and is associated with higher in-hospital mortality rates and poorer OS after discharge. Oncologists should be aware of the prognostic implications of PD during admission and align goals of care with their patients.
- 1 July 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 10 (10) , e2400063
Unplanned Hospital Admissions in Patients With Solid Tumors in Brazil: Causes and Progressive Disease's Impact on Outcomes
PURPOSE: Most patients with cancer will be hospitalized throughout the disease course. However, most evidence on the causes and outcomes of these hospitalizations comes from administrative data or small retrospective studies from high-income countries. METHODS: This study is a retrospective cohort of patients with solid tumors hospitalized from February 1, 2021, to December 31, 2021, in a tertiary cancer center in São Paulo, Brazil. We collected data on cancer diagnosis, symptoms at admission, hospitalization diagnosis, and survival clinical outcomes during in-hospital stay (in-hospital mortality) and after discharge (readmission rates and overall survival [OS]). Progressive disease (PD) diagnosis during admission was retrieved from manual chart review if explicitly stated by the attending physician. We modeled in-hospital mortality and postdischarge OS with logistic regression and Cox proportional hazards models, respectively. RESULTS: A total of 3,726 unique unplanned admissions were identified. The most common symptoms at admission were pain (40.6%), nausea (16.8%), and dyspnea (16.1%). PD (34.0%), infection (31.1%), and cancer pain (13.4%) were the most frequent reasons for admission. The in-hospital mortality rate was 18.9%. Patients with PD had a high in-hospital mortality rate across all tumor groups and higher odds of in-hospital death (odds ratio, 3.5 [95% CI, 3.0 to 4.2]). The 7-, 30-, and 90-day readmission rates were 11.9%, 33.5%, and 54%, respectively. The postdischarge median OS (mOS) was 12.6 months (95% CI, 11.6 to 13.7). Poorer postdischarge survival was observed among patients with PD (mOS, 5 months v 18 months; P < .001; hazard ratio, 2.4 [95% CI, 2.1 to 2.6]). CONCLUSION: PD is a common diagnosis during unplanned hospitalizations and is associated with higher in-hospital mortality rates and poorer OS after discharge. Oncologists should be aware of the prognostic implications of PD during admission and align goals of care with their patients.